Table 3. Comparison of de novo Masaoka stage IVa and recurrences after primary surgery.
| Median age | Sex | MG | Neo | Adjuvant | Masaoka stage | Histology | Median time to recurrence (months) | Median time to re-recurrence (months) | Number of operation | 3-years survival (%) | 5-years survival (%) | 10-years survival (%) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage at primary operation ≤ III n: 8 |
37.4 ± 11.2 [22–58] |
5 ♂ 2 ♀ | 7 | 5 | None: 2 CT: 3 RT: 0 CT-RT: 3 |
II: 6 III: 2 |
B1: 4 B2: 2 B3: 1 C: 1 |
51.4 ± 39.1 | 38.7 ± 26.0 | 5 secondary, 3 tertiary |
100 | 100 | 38 |
| Stage at primary operation = IVa (de novo IVa) n: 31 |
42.9 ± 12.0 [17–70] |
20 ♂ 11 ♀ |
11 | 20 | None: 2 CT: 10 RT: 8 CT-RT: 11 |
IVa: 31 | B1: 4 B2: 14 B3: 5 C: 8 |
35.7 ± 24.3 | 30.0 ± 0 | 26 primary 4 secondary, 1 tertiary |
91 | 91 | 80 |
MG: myasthenia gravis; CT-RT: chemotherapy and radiotherapy; CT: chemotherapy; RT: radiotherapy